Eye Disease & Ophthalmology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis

This study is exploring the safety and effectiveness of Tebiovio® (adalimumab) injections for adults with non-infectious uveitis, a condition that causes inflammation inside the eye. If successful, this treatment may offer a new way to better control eye inflammation and help prevent vision loss. The trial aims to enroll 30 participants and is currently not recruiting.

AVIGA3 (Cohort 2.0)

This trial is testing a remote monitoring system that uses eye gaze tracking to watch for changes in people with age-related macular degeneration. This technology could allow patients to check their vision health from home and alert doctors to any early signs of disease returning. The study is recruiting adults aged 40 to 79 in Singapore and may provide a more convenient way to manage this common eye condition.

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

This Phase 2 trial is testing a gene therapy called laruparetigene zovaparvovec in males with X-Linked Retinitis Pigmentosa, a rare inherited eye disease that causes vision loss. The treatment aims to preserve or improve vision by addressing the genetic cause of the disease. The study is active but not recruiting, with results expected after a year of follow-up.

GlaukomAI: Clinical Validation of an AI System for Early Glaucoma Screening

This study is evaluating an artificial intelligence (AI) software named GlaukomAI designed to help detect glaucoma early using images of the eye. Early diagnosis is key to slowing glaucoma’s progression and reducing vision loss. The trial is recruiting in Italy and involves a single visit with standard eye examinations.

Visual Performance of Highly Aspherical Lenslet Spectacles in Children (Ancillary to WS10246)

This trial is comparing new highly aspherical lenslet (HAL) spectacles to regular single vision lenses in children with myopia, or nearsightedness. The goal is to see if these new lenses can improve vision and reading ability better than current options. The study enrolled 88 children in the United States and may lead to better glasses for young patients.

This week saw ongoing efforts across multiple eye conditions, from inflammatory diseases and genetic disorders to common issues like glaucoma and myopia. These trials highlight new technologies including gene therapies, AI diagnostics, and innovative eyewear that could improve how patients manage eye health. Continued research in these areas offers hope for earlier detection, better treatment, and improved quality of life.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.